HR and breast cancer: In the early stage breast cancer setting, treatment decisions are guided by clinical subtypes, namely hormone receptor (HR) positive (HR+/HER2−), human epidermal growth factor receptor 2 amplified (HER2+) and triple-negative breast cancer (TNBC).